Clinical Research Papers:

RET mutation p.S891A in a Chinese family with familial medullary thyroid carcinoma and associated cutaneous amyloidosis binding OSMR variant p.G513D

Xiao-Ping Qi _, Jian-Qiang Zhao, Zhen-Guang Chen, Jin-Lin Cao, Juan Du, Nai-Fang Liu, Feng Li, Mao Sheng, Er Fu, Jian Guo, Hong Jia, Yi-Ming Zhang and Ju-Ming Ma

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2015; 6:33993-34003. https://doi.org/10.18632/oncotarget.4992

Metrics: PDF 1619 views  |   HTML 2256 views  |   ?  


Xiao-Ping Qi1, Jian-Qiang Zhao2, Zhen-Guang Chen1, Jin-Lin Cao1, Juan Du3, Nai-Fang Liu1, Feng Li1, Mao Sheng1, Er Fu1, Jian Guo1,5, Hong Jia4 Yi-Ming Zhang1, Ju-Ming Ma1

1Department of Oncologic and Urology Surgery, the 117th PLA Hospital, Wenzhou Medical University, Hangzhou 310004, Zhejiang Province, China

2Department of Head and Neck Surgery, Zhejiang Cancer Hospital, Hangzhou 310022, Zhejiang Province, China

3Zhejiang Academy of Medical Sciences, Hangzhou 310007, Zhejiang Province, China

4Institute of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College, Nanjing 210042, Jiangsu Province, China

5Department of Dermatology, the 117th PLA Hospital, Wenzhou Medical University, Hangzhou 310004, Zhejiang Province, China

Correspondence to:

Xiao-Ping Qi, e-mail: [email protected]

Keywords: thyroid neoplasia, medullary thyroid carcinoma, cutaneous amyloidosis, RET mutation, OSMR variant

Received: March 05, 2015     Accepted: August 14, 2015     Published: August 22, 2015


There are no reports on the relationship between familial medullary thyroid carcinoma (FMTC) associated with cutaneous amyloidosis (CA) and RET or OSMR/IL31RA gene mutations. In this study, we investigated a Chinese family with FMTC/CA and found a recurrent RET c.2671T>G (p.S891A) mutation in six of 17 family members. Three of the six p.S891A mutation carriers presented with medullary thyroid carcinoma (MTC). Of them, three (two with and one without MTC) were diagnosed as having combined lichen/macular biphasic CA. We also identified a novel RET variant, c.1573C>T (p.R525W) in five members. Of them, three carriers had no evidence of thyroid/skin or basal serum/stimulated calcitonin abnormalities. In vitro cell proliferation assay indicated that oncogenic activity of RET p.S891A was slightly enhanced by p.R525W, whereas p.R525W alone had no effect on cell proliferation. Meanwhile, we identified a novel OSMR variant, c.1538G>A (p.G513D) in seven members. We noticed that three OSMR p.G513D carriers presenting with CA also had the RET p.S891A mutation. Our investigation indicated that the RET p.S891A mutation combined with OSMR p.G513D may underlie a novel phenotype manifesting as FMTC and CA.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 4992